Skip to Content

Bendamustine Dosage

Applies to the following strength(s): 25 mg/mL ; 25 mg ; 100 mg ; 90 mg/mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Chronic Lymphocytic Leukemia

100 mg/m2 IV on Days 1 and 2 of a 28-day cycle
Duration of Therapy: Up to 6 cycles

Comments:
-Administer this drug via IV infusion over 10 or 30 minutes; consult the manufacturer product information for specific IV infusion time period.
-Efficacy of this drug relative to first-line therapies other than chlorambucil has not been established.

Use: Treatment of chronic lymphocytic leukemia

Usual Adult Dose for non-Hodgkin's Lymphoma

120 mg/m2 IV on Days 1 and 2 of a 21-day cycle
Duration of Therapy: Up to 8 cycles

Comments: Administer this drug via IV infusion over 10 or 60 minutes; consult the manufacturer product information for specific IV infusion time period.

Use: Treatment of indolent B-Cell non-Hodgkin lymphoma that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Renal Dose Adjustments

-Mild to Moderate Renal Dysfunction: Use with caution.
-Severe Renal Dysfunction (CrCl less than 40 mL/min): Not recommended.

Liver Dose Adjustments

-Mild Liver Dysfunction: Use with caution.
-Moderate Liver Dysfunction (AST or ALT 2.5 to 10 x Upper Limit of Normal and Total Bilirubin 1.5 to 3 x ULN): Not recommended.
-Severe Liver Dysfunction (Total Bilirubin greater than 3 x ULN): Not recommended.

Dose Adjustments

Chronic Lymphocytic Leukemia (CLL) or Non-Hodgkin Lymphoma (NHL):
Grade 4 Hematologic Toxicity or Clinically Significant Grade 2 or Greater Non-Hematologic Toxicity: Delay treatment; reinitiate therapy at a physician's discretion once non-hematologic toxicity has recovered to Grade 1 or less and/or absolute neutrophil count (ANC) 1 x 10(9)/L or greater and platelets 75 x 10(9)/L or greater; dose reduction may be warranted.

CLL:
Grade 3 or Greater Hematologic Toxicity: Reduce dose to 50 mg/m2 on Days 1 and 2 of each cycle.
-If Grade 3 or greater toxicity recurs, reduce dose to 25 mg/m2 on Days 1 and 2 of each cycle.
-Dose re-escalation in subsequent cycles may be considered per physician discretion.

Clinically Significant Grade 3 or Greater Non-Hematologic Toxicity: Reduce dose to 50 mg/m2 on Days 1 and 2 of each cycle.
-Dose re-escalation in subsequent cycles may be considered per physician discretion.

NHL:
Grade 4 Hematologic Toxicity or Grade 3 or Greater Non-Hematologic Toxicity: Reduce dose to 90 mg/m2 on Days 1 and 2 of each cycle.
-If Grade 4 hematologic or Grade 3 or greater non-hematologic toxicity recurs, reduce dose to 60 mg/m2 on Days 1 and 2 of each cycle.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

This drug is dialyzable to a small extent; however, no dose adjustment guidelines have been reported.

Other Comments

Administration Advice:
-Allow the drug vial to reach room temperature (15 to 30 C/59 to 86 F) prior to use.
-Consult the manufacturer product information for IV infusion administration technique and timing.

Storage Requirements:
-Store under refrigeration (2 to 8 C/36 to 46 F) and retain in original carton to protect from light.

Reconstitution/Preparation Techniques:
-Consult the manufacturer product information.

IV Compatibility:
-Consult the manufacturer product information for compatible diluents.

General:
-There is no specific antidote for overdosage. Effective countermeasures to control hematological side effects include bone marrow transplantation, transfusions (platelets, concentrated erythrocytes), or hematological growth factors.
-If this drug comes into contact with skin, mucous membranes, or eyes, immediately wash skin thoroughly with soap and water, flush contaminated mucous membranes thoroughly with water, and rinse eyes with physiological saline solution.

Monitoring:
-Skin reactions
-CBC and blood chemistry
-IV infusion site reactions

Patient Advice:
-This drug may cause side effects such as drowsiness that can affect your ability to perform certain activities; avoid driving and activities such as operating machinery until you know how this drug affects you.

Hide